Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
|
|
- Hilary Hall
- 5 years ago
- Views:
Transcription
1 Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The speaker will directly disclosure the use of products for which are not labeled (e.g., off label use) or if the product is still investigational. 14 th Annual California Cancer Conference Consortium August 1-12, 218
2 Agenda Management of Younger Patients With AML Management of Older Patients With AML Management of Relapsed AML Management of Newly Diagnosed ALL Management of Relapsed ALL
3 RATIFY: First-line Chemotherapy ± Midostaurin in FLT3-Mutated AML Randomized phase III study Induction* (1-2 cycles) Consolidation (up to 4 cycles) Maintenance (12 cycles) Stratified by ITD/TKD Pts with ND FLT3- positive AML, aged yrs, and stratified according to FLT3 subtype (TKD or ITD high or low) (N = 717) Daunorubicin 6 mg/m 2 IVP D1-3 + Cytarabine 2 mg/m 2 /d IVCI D1-7 + Midostaurin 5 mg PO BID D8-21 (n= 36) Daunorubicin 6 mg/m 2 IVP D1-3 + Cytarabine 2 mg/m 2 /d IVCI D1-7+ Placebo D8-21 (n = 357) CR CR Cytarabine 3 g/m 2 over 3h q12h D1,3,5 + Midostaurin 5 mg PO BID D8-21 (n = 231) Cytarabine 3 g/m 2 over 3h q12h D1,3,5 + Placebo D8-21 (n = 21) Midostaurin 5 mg PO BID D1-28 (n = 12) Placebo D1-28 (n = 85) Stone RM, et al. N Engl J Med. 217;377: *Hydroxyurea allowed for 5 days prior to induction therapy.
4 Probability of Survival (%) RATIFY: Overall Survival Pts at Risk, n Midostaurin Placebo mos, Mos (95% CI) CR 59% CR 54% Mos Midostaurin Placebo (31.5-NR) 25.6 ( ) 1-sided P =.9 by stratified log-rank test Overall ITD (high) ITD (low) TKD Pts HR (95% CI) Midostaurin Better.78 ( ).8 ( ).81 ( ).65 ( ) Placebo Better P Value.9 (1 sided).19 (2 sided).19 (2 sided).1 (2 sided) Stone RM, et al. N Engl J Med. 217;377:
5 OS (%) RFS (%) Standard of Care Induction Chemotherapy ± Gemtuzumab Ozogamicin Gemtuzumab ozogamicin 3 mg/m 2 on Days 1, 4, 7 of induction and Day 1 of each consolidation cycle 1 OS 1 RFS Pts at Risk, n Control Gemtuzumab ozogamicin Mos Log-rank P = Castaigne S, et al. Lancet. 212;379: Pts at Risk, n Control Gemtuzumab ozogamicin Mos Log-rank P =
6 OS (%) OS (%) AML15: Addition of Gemtuzumab Ozogamicin to Cytarabine-Based Induction Therapies in AML OS: All Pts OS: Favorable Karyotype AML 1 75 No gemtuzumab ozogamicin Gemtuzumab ozogamicin 1 75 No gemtuzumab ozogamicin Gemtuzumab ozogamicin 79% P =.3 Pts, n No gemtuzumab ozogamicin 557 Gemtuzumab ozogamicin Yrs Events, n Obs. Exp % 41% P =.3 No gemtuzumab ozogamicin Gemtuzumab ozogamicin Pts, n Events, n Obs. Exp Yrs 51% Burnett AK, et al. J Clin Oncol. 211;29:
7 RR (Probability) RR (Probability) CD33 Splicing Polymorphisms in Pediatric AML Following Gemtuzumab Ozogamicin 1. rs = CC 1. rs = CT.75 P <.1.75 P < No-GO (n = 145).5 No-GO (n = 11).25 GO (n = 154).25 GO (n = 125) Yrs From End of Induction 1 Yrs From End of Induction 1 Lamba JK, et al. J Clin Oncol. 217;35:
8 Older Patients
9 OS Outcomes in Older Adults With AML (Aged Yrs) 1. OS by Leukemia Therapy, Stratified by Charlson Comorbidity Index (CCI) Treated, CCI = Treated, CCI = 2 Untreated, CCI = 1 Mos After Diagnosis Treated, CCI = 1 Untreated, CCI = Untreated, CC1 = 2 Oran B, et al. Haematologica. 212;97:
10 Number of Driver Mutations Increase With Age in Pts With AML No. Mutated Genes per Pt, by Age Category P <.1 P = No. Mutated Genes < 4 Yrs 4-59 Yrs 6 Yrs Metzeler KH, et al. Blood. 216;128:
11 Proportional Surviving Mutations in Older Pts With AML Variables* Pts With Alteration, % All Older Younger P Value FLT3/ITD >.999 FLT3/TKD NRAS KRAS PTPN KIT JAK >.999 WTI NPM CEBPA RUNX MLL/PTD ASXL <.1 IDH IDH *For all variables except Cohesin, n = 462; for Cohesin, n = 411. Tsai CH, et al. Leukemia. 216;3: Variables* Pts With Alteration, % All Older Younger P Value TET <.1 DNMT3A TP Cohesin > P =.42 No adverse genetic alterations (n = 37) At least 1 adverse genetic alteration (n = 32) OS (Mos)
12 AML Ontogeny Can Be Mutationally Defined Gene Color Specificity > 95% for sec. AML > 95% for de novo AML < 95% for sec. AML < 95% for de novo AML SRSF2 ZRSR2 SF3B1 ASXL1 BCOR EZH2 U2AF1 STAG2 NF1 RUNX1 CBL NRAS TET2 GATA2 TP53 KRAS PTPN11 IDH1 IDH2 SMC1A RAD21 FLT3 DNMT3A SMC3 CEBPA NPM1 11q23-rearranged CBF-rearranged Lindsley RC, et al. Blood. 215;125: Secondary AML De Novo AML Mutated cases, n (%) 19 (2) 7 (8) 1 (11) 3 (32) 7 (8) 8 (9) 15 (16) 13 (14) 6 (6) 29 (31) 5 (5) 21 (23) 19 (2) 2 (2) 14 (15) 7 (8) 5 (5) 1 (11) 1 (11) 3 (3) 2 (2) 18 (19) 18 (1) 2 (2) 3 (3) 5 (5) Odds Ratio 1 (1) 1 (1) 5 (3) 2 (2) 3 (2) 8 (4) 3 (2) 7 (4) 19 (11) 3 (2) 15 (8) 17 (9) 2 (1) 16 (9) 8 (4) 9 (5) 2 (11) 19 (11) 7 (4) 5 (3) 5 (28) 51 (28) 7 (4) 13 (7) 54 (3) 11 (6) 19 (9) P Value < < <.1.2 <.1
13 Pts Achieving CR After Intensive Induction CT (%) Event-Free Survival (%) Differential Outcomes in Pts With de novo AML Based on Mutational Profile Clinically defined de novo AML, age 6 yrs No CR CR 1 5 Clinically defined de novo AML, age 6 yrs De novo/pan-aml Secondary-type TP53 mutated Mos Lindsley RC, et al. Blood. 215;125:
14 Older Age Remains Independent Prognostic Factor in AML Variable Age 6 yrs Female sex AML category De novo AML Secondary AML Therapy-related AML ECOG performance status -1 2 WBC count (5,/μL increase) MRC cytogenetic risk category Intermediate Favorable Adverse HR for Death (95% CI) 2.14 ( ).82 ( ) ( ) 2.24 ( ) ( ) 1.1 ( ) 1.41 ( ) 1.65 ( ) P Value < < <.1 <.1 Metzeler KH, et al. Blood. 216;128: Slide credit: clinicaloptions.com
15 CPX nm bilamellar liposomes 5:1 molar ratio of cytarabine to daunorubicin 1 unit = 1.-mg cytarabine plus.44-mg daunorubicin Lancet JE, et al. ASCO 216. Abstract 7.
16 Prevalence of Synergy or Antagonism (% of Cell Screened) First-line CPX-351 in Newly Diagnosed Elderly AML: Phase II Study 24 CPX-351: liposomal formulation [1] Cytarabine + daunorubicin in 5:1 fixed molar ratio Taken up by cells, with preference for bone marrow Phase II study in elderly AML [2] Aged 6-75 yrs, fit for chemo 2:1 randomization to CPX-351 (1 U/m 2 IV Days 1, 3, 5) vs CR/CRi rate superior with CPX-351 (P =.7) CPX-351: 67%; 7 + 3: 51% Percent synergistic Percent antagonistic 1:1 1:5 1:1 5:1 1:1 CYT:DN Molar Ratios 1. Tardi P, et al. Leuk Res. 29;33: Lancet JE, et al. Blood. 214;123:
17 First-line CPX-351 in High-Risk AML: Phase III Study Design Stratified by age (6-69 yrs vs 7-75 yrs), disease characteristics* Consolidation 1-2 cycles in pts with CR or CRi Pts with previously untreated high-risk AML,* 6-75 yrs of age, ECOG PS -2, ability to tolerate intensive therapy (N = 39) CPX-351 Induction, 1-2 cycles 1 units/m 2 C1: Days 1, 3, 5; C2: Days 1,3 (n = 153) 7+3 Induction, 1-2 Cycles Cytarabine: 1 mg/m 2 /day Daunorubicin: 6 mg/m 2 C1: Ara-C, 7 days; Daun, 3 days C2: Ara-C, 5 days; Daun, 2 days (n = 156) Until death or 5-yr follow-up Primary endpoint: OS *Therapy-related AML; AML with history of MDS ± prior HMA therapy or CMML; de novo AML with MDS karyotype. CPX-351 arm: 65 units/m 2, Days 1, 3; arm: same dosing as reinduction (C2). Secondary endpoints: event-free survival, CR + CRi, 6-day mortality Lancet JE, et al. ASCO 216. Abstract 7.
18 Survival (%) First-line CPX-351 in High-Risk AML: OS ITT Analysis Population CPX Events, n/n 14/ /156 HR:.69 P =.5 Median Survival, Mos (95% CI) 9.56 ( ) 5.95 ( ) Mos From Randomization Lancet JE, et al. ASCO 216. Abstract 7.
19 OS (%) First-Line CPX-351: Survival Landmarked From Time of Transplant 1 8 Kaplan-Meier Curve for OS Landmarked at Time of Stem Cell Transplant CPX Events, n/n 18/52 26/39 mos (95% CI) Not reached 1.25 ( ) HR:.46; log-rank P = CPX CPX Mos From Stem Cell Transplant Lancet JE, et al. ASH 216. Abstract 96.
20 CPX-351: Toxicity Considerations Grade 3-5 Nonhematologic AE, n (%) CPX-351 (n = 153) (n = 151) All Pts (N = 34) Febrile neutropenia 14 (68) 17 (71) 211 (69) Pneumonia 3 (2) 22 (15) 52 (17) Hypoxia 2 (13) 23 (15) 43 (14) Sepsis 14 (9) 11 (7) 25 (8) Hypertension 16 (1) 8 (5) 24 (8) Respiratory failure 11 (7) 1 (7) 21 (7) Complete Recovery Counts for Pts With CR/CRi Pts receiving 1 induction, n Median, days Pts receiving 2 inductions, n Median, days ANC 5/µL CPX Plts 5,/µL CPX Fatigue 11 (7) 9 (6) 2 (7) Bacteremia 15 (1) 3 (2) 18 (6) Ejection fraction dec. 8 (5) 8 (5) 16 (5) Lancet JE, et al. ASCO 216. Abstract 7.
21 OS Outcomes With Various Treatment Approaches in Pts Aged > 7 Yrs With AML Pts at Risk, n HMA High intensity Supportive care Low intensity Dhulipala VC, et al. ASH 215. Abstract Mos HMA High intensity Supportive care Low intensity Censored Slide credit: clinicaloptions.com
22 Probability of Survival Survival Outcomes in Pts With TP53-Mutated AML TP53 wt; not complex karyotype TP53 mut; not complex karyotype TP53 wt; complex karyotype TP53 mut; complex karyotype Yrs Papaemmanuil E, et al. N Engl J Med. 216;374: Slide credit: clinicaloptions.com
23 Variant Allele Frequency Survival (%) Extended (1-Day) Decitabine in TP53-Mutated AML Clearance Rate of TP53 Mutations Survival After SCT, by TP53 Mutation Status Transplantation and TP53 mutation Transplantation and wild-type TP P =.99 Pts at Risk, n TP53 mutation Wild-type TP Days Welch JS, et al. N Engl J Med. 216;375:
24 Ivosidenib (AG-12) Somatic IDH1 and IDH2 mutations result in accumulation of oncometabolite 2-HG [1] Epigenetic changes, impaired cellular differentiation midh identified in multiple solid and hematologic tumors [1,2] Mutation Frequency, % midh1 midh2 Pts With AML [2] Ivosidenib (AG-12): first-in-class, oral, potent, reversible, selective inhibitor of midh1 enzyme [3] 1. Mondesir J, et al. J Blood Med. 216;7: Medeiros BC, et al. Leukemia. 217;31: DiNardo CD, et al. ASH 217. Abstract 725.
25 Ivosidenib (AG-12) vs Enasidenib (AG-221) Efficacy/toxicity profile of midh1 and midh2 inhibitor appears similar Parameter midh1 Inhibitor: Ivosidenib [1] Disease(s) evaluated (N = 258) R/R AML, other hematologic malignancies Testing of combination therapies ongoing midh2 Inhibitor: Enasidenib [2] (N = 239) R/R AML, MDS CR/CRh at RP2D, % CR duration, mos Differentiation syndrome, % DNA methyltransferase inhibitors: synergistic effect on release of differentiation block in midh/leukemia models in vitro [3] 1. DiNardo CD, et al. ASH 217. Abstract Stein EM, et al. Blood. 217;13: DiNardo CD, et al. ASH 217. Abstract 639.
26 Venetoclax With Decitabine or Azacitidine for AML: Background AML diagnosed at median age of 68 yrs, [1] yet elderly patients often ineligible or refractory to intensive induction CT [2] BCL-2: antiapoptotic protein expressed at high levels in AML, associated with poor outcomes and CT resistance [3] Venetoclax: oral BCL-2 inhibitor associated with in vitro antileukemic activity synergistic with hypomethylating agents (ie, azacitidine) [4] Venetoclax may serve as efficacious, low-intensity treatment for AML in elderly patients ineligible for standard induction CT Current report assessed safety, efficacy of venetoclax in combination with azacitidine or decitabine in elderly patients with previously untreated AML ineligible for standard induction chemotherapy [5] 1. NIH. Cancer stat facts: leukemia - acute myeloid leukemia (AML). 2. Kantarjian H, et al. Blood. 21;116: Pan R, et al. Blood. 215;126: Bogenberger JM, et al. Leuk Lymphoma. 215;56: DiNardo CD, et al. ASCO 218. Abstract 71. Slide credit: clinicaloptions.com
27 Venetoclax With Decitabine or Azacitidine for AML: Study Design Multicenter, open-label phase Ib dose-escalation and dose-expansion trial (data cutoff: July 7, 217) Patients with untreated AML; aged 65 yrs; ineligible for standard induction; ECOG PS -2; no prior HMA/CT for antecedent hematologic disorder, CAR T-cell tx, other experimental tx; no favorable-risk cytogenetics*; no active CNS involvement; WBC count 25 x 1 9 /L; no HIV, HBV, HCV infection (N = 145) Dose Escalation Venetoclax ramped up to 4, 8, or 12 mg QD + Decitabine 2 mg/m 2 on Days 1-5 or Azacitidine 75 mg/m 2 on Days 1-7 in 28-day cycles Dose Expansion Venetoclax ramped up to 4 or 8 QD + Decitabine 2 mg/m 2 on Days 1-5 or Azacitidine 75 mg/m 2 on Days 1-7 in 28-day cycles *Core binding factor: inv(16), t(16;16), t(8;21), or t(15;17). Venetoclax ramped up during cycle 1: Day 1, 1 mg; Day 2, 2 mg; Day 3, 4 mg; Day 4, 8 mg; Day 5, 12 mg (11 patients). On reaching assigned dose level of 4, 8, or 12 mg QD, that dose was continued for rest of cycle. Primary endpoint: safety Secondary endpoints: CR, CRi, DoR, OS DiNardo CD, et al. ASCO 218. Abstract 71. Exploratory endpoint: MRD (< 1-3 leukemic cells at any measurement as detected by multicolor flow cytometry) Slide credit: clinicaloptions.com
28 Venetoclax With Decitabine or Azacitidine for AML: Baseline Characteristics Median follow-up of 15.6 mos Characteristic, n (%) Median age, yrs (range) 75 yrs, n (%) All Patients (N = 145) 74 (65-86) 62 (43) Male 81 (56) ECOG PS 1 2 BL bone marrow blasts 3% 31% to 5% > 5% 32 (22) 9 (62) 23 (16) 44 (3) 48 (33) 53 (37) Median mos on study (range) 8.9 ( ) DiNardo CD, et al. ASCO 218. Abstract 71. Characteristic, n (%) All Patients (N = 145) BL hydroxyurea use 14 (1) Cytogenetics Intermediate risk Favorable 74 (51) 71 (49) Secondary AML 36 (25) Slide credit: clinicaloptions.com
29 Venetoclax With Decitabine or Azacitidine for AML: Response and Survival Outcome CR + CRi, % CR CRi MRD negativity in patients with CR/CRi, n/n (%) Median DoR in patients with CR/CRi, mos (95% CI) Intermediate risk Poor risk de novo AML Secondary AML All Patients* (N = 145) Venetoclax 4 mg Venetoclax 8 mg Azacitidine (n = 29) Decitabine (n = 31) Azacitidine (n = 37) Decitabine (n = 37) CR/CRi rates in subgroups: intermediate-risk cytogenetics, 74%; poor-risk cytogenetics, 59%; de novo AML, 67%; secondary AML, 67%; aged < 75 yrs, 69%; aged 75 yrs, 64% /97 (29) 1/22 (45) 7/22 (32) 7/21 (33) 3/27 (11) (11.-NR) 6.7 ( ) 9.4 ( ) NR (12.5-NR) NR (5.6-NR) (5.1-NR) ( ) Median OS, mos (95% CI) 17.5 (12.3-NR) NR (11.-NR) 17.5 (1.3-NR) *Including 11 patients who received venetoclax at 12 mg. DiNardo CD, et al. ASCO 218. Abstract (5.9-NR) Slide credit: clinicaloptions.com
30 Venetoclax With Decitabine or Azacitidine for AML: Conclusions In this phase Ib dose-escalation and dose-expansion trial, venetoclax plus decitabine or azacitidine was well tolerated with deep, durable responses in elderly patients with previously untreated AML CR/CRi rate in all patients: 67% Promising CR/CRi rates observed in high-risk subgroups: poor-risk cytogenetics (59%), secondary AML (67%), and 75 yrs of age (64%) After median follow-up of 15.6 mos, median OS was 17.5 mos in all patients (1-yr survival rate ~ 5%) MRD negativity observed in 45% of patients who received venetoclax 4 mg + azacitidine Investigators suggested that venetoclax at 4 mg QD in combination with decitabine or azacitidine offers optimal risk benefit profile DiNardo CD, et al. ASCO 218. Abstract 71. Slide credit: clinicaloptions.com
31 Acute Lymphoblastic Leukemia
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
Acute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationAcute Myeloid Leukemia: State of the Art in 2018
Acute Myeloid Leukemia: State of the Art in 2018 Harry P. Erba, MD, PhD Professor, Department of Medicine Director, Leukemia Program Duke University Durham, NC Treatment Paradigm of Adults with AML Fit
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA. Dr Rob Sellar UCL Cancer Institute, London, UK
ESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA Dr Rob Sellar UCL Cancer Institute, London, UK OVERVIEW Main focus on patients fit for intensive treatment Biological and Clinical Heterogeneity
More informationHow the Treatment of Acute Myeloid Leukemia is Changing in 2019
How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City
More informationTREATMENT UPDATES IN ACUTE LEUKEMIA. Shannon McCurdy, MD University of Pennsylvania
TREATMENT UPDATES IN ACUTE LEUKEMIA Shannon McCurdy, MD University of Pennsylvania TIMELINE FOR FDA APPROVED AGENTS FOR AML Midostuarin Enasidenib Cytarabine + Daunorubicin (7+3) Gemtuzumab Ozogamicin
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationIDH1 AND IDH2 MUTATIONS
Mutant Isocitrate Dehydrogenase (midh) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationIvosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study
7000 Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study Daniel A Pollyea 1, Courtney D DiNardo 2, Stéphane de Botton 3, Eytan M Stein
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationEnasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationSubset Specific Therapy in High Risk Myeloid Malignancies. Are We Making Progress? Olatoyosi Odenike, MD. The University of Chicago
Subset Specific Therapy in High Risk Myeloid Malignancies. Are We Making Progress? Olatoyosi Odenike, MD The University of Chicago Disclosure Information 23 rd Annual Developmental Therapeutics Symposium
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More informationMolecularly Targeted Therapies - Strategies of the AMLSG
Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationANCO: ASCO Highlights 2018 Hematologic Malignancies
ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships
More informationNeue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML)
Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML) Prof. Hartmut Döhner Klinik für Innere Medizin III, Universitätsklinikum Ulm Midostaurin
More informationHematologic Malignancies: Top Ten Advances Impacting Clinical Practice
Hematologic Malignancies: Top Ten Advances Impacting Clinical Practice Adam D. Cohen, MD Abramson Cancer Center University of Pennsylvania June 14, 2018 Please note that some of the studies reported in
More informationNovel Induction and Targeted Strategies in Acute Myeloid Leukemia
Novel Induction and Targeted Strategies in Acute Myeloid Leukemia Eytan M. Stein, MD Leukemia Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Current Paradigms
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationAcute Myeloid Leukemia: Targets and Curability, so Close But a Journey So Far
Acute Myeloid Leukemia: Targets and Curability, so Close But a Journey So Far Martin S. Tallman, M.D. Chief, Leukemia Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More information2/10/2017. Updates in Acute Leukemia Therapy Blood Cancer Incidence in the United States, Leukemia Incidence in the Unites States, 2016
Updates in Acute Leukemia Therapy 2017 Aaron Logan, MD, PhD UCSF Division of Malignant Hematology and Blood and Marrow Transplantation aaron.logan@ucsf.edu @hemedoc Blood Cancer Incidence in the United
More informationBest of ASH: Acute leukemia. Frédéric Baron
Best of ASH: Acute leukemia Frédéric Baron I Acute Myeloid Leukemia Flt3 inhibitors (ratify, sorafenib after HCT) 5 other important abstracts (in brief) Mutated genes in AML FLT3: The Cancer Genome Atlas
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationUpdates in the Management of Acute Myeloid Leukemia
Updates in the Management of Acute Myeloid Leukemia Lydia Benitez, harmd, BCO 2017 TOA Conference I have no conflicts of interest with relation to the content of this presentation 4 Objectives Describe
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationMyelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans
Myelodysplastic Syndromes Post-ASH meeting 2014 Marie-Christiane Vekemans Agenda New biological developments Risk assessment and prognostic factors New therapeutic options Agenda New biological developments
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY
ENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationRisk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome
Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %
More informationNext Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory
Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope Acute Myeloid Leukemia Gene
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationThe Past, Present, and Future of Acute Myeloid Leukemia
The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationUpdates in Treatment Strategies for Acute Leukemia. Alexander Perl, MD Assistant Professor, Hematology/Oncology University of Pennsylvania 1/22/2016
Updates in Treatment Strategies for Acute Leukemia Alexander Perl, MD Assistant Professor, Hematology/Oncology University of Pennsylvania 1/22/2016 What is happening to standard of care in 2017? AML treatment
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationThe Evolving Treatment Landscape in AML
The Evolving Treatment Landscape in AML Elias Jabbour, MD Associate Professor Section Chief, Acute Lymphocytic Leukemia Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationTreatment of Low-Blast Count AML. Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata
Treatment of Low-Blast Count AML Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata Definition of Low-Blast Count AML Blast counts 20-30%, or > 10%? v Retrospective
More informationManagement of Myelodysplastic Syndromes
Management of Myelodysplastic Syndromes Peter L. Greenberg, MD Stanford Cancer Institute Myelodysplastic Syndromes: Clinical & Molecular Advances for Disease Classification and Prognostication MDSs: A
More informationLearning Objectives. Case A: Presentation. Case A Question Not included in Activity Survey. Acute Leukemia: Diagnosis and Prognosis
Learning Objectives Improve awareness of FDA-approved agents and/or therapies under development for the treatment of AML and ALL Incorporate FDA-approved agents and therapies under development into treatment
More informationAML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013
AML in elderly D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013 AML is predominantly a disease of the elderly incidence 2 3/100.000 SEER Cancer Statistics, National Cancer Institute, USA 2002 2006
More informationPathogenesis and management of CMML
Pathogenesis and management of CMML Raphaël Itzykson, Hôpital Saint-Louis, Paris International Conference of the Korean Society of Hematology March 29th 2018 대한혈액학회 Korean Society of Hematology COI disclosure
More informationANCO Hematological Malignancies Update: The year in review. Midostaurin Vyxeos Gemtuzumab ozogamicin Enasidenib. The year in preview
ANCO Hematological Malignancies Update: Gabriel Mannis, MD Assistant Professor, and Marrow Co-Director, Cancer Immunotherapy Clinic Acute Leukemia Sacramento, CA June 16, 2018 OVERVIEW Overview The year
More informationMeet-the-Expert: AML Treating older patients with AML
Meet-the-Expert: AML Treating older patients with AML Sergio Amadori Tor Vergata University Hospital Rome Istanbul 2012 AML in older patients Poor prognosis Minority treated with intensive Cx Treatment
More informationMyelodysplastic syndromes Impact of Biology. Lionel Adès Hopital Saint Louis Groupe Francophone des SMD. Épidémiologie
Myelodysplastic syndromes Impact of Biology Lionel Adès Hopital Saint Louis Groupe Francophone des SMD Épidémiologie Incidence : 3 à 6 / 100 000 hab. / An Prédomine chez les sujets âgés Augmentation de
More informationNEW THERAPIES IN ACUTE MYELOID LEUKEMIA (AML) Maho Hibino, PharmD, BCOP Oncology Clinical Specialist Wake Forest Baptist Health August 3, 2018
NEW THERAPIES IN ACUTE MYELOID LEUKEMIA (AML) Maho Hibino, PharmD, BCOP Oncology Clinical Specialist Wake Forest Baptist Health August 3, 2018 OBJECTIVES Recognize new medications that received FDA approval
More informationDisclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:
Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance
More informationAML Handout August 3, 2018
NEW THERAPIES IN ACUTE MYELOID LEUKEMIA (AML) Maho Hibino, PharmD, BCOP Oncology Clinical Specialist Wake Forest Baptist Health August 3, OBJECTIVES Recognize new medications that received FDA approval
More informationAmerican Society of Hematology Annual Meeting, San Diego, CA USA, 2 Dec 2018
Uproleselan (GMI-1271), an E-selectin antagonist, improves efficacy and safety of chemotherapy in R/R and newly diagnosed older patients with AML: final, correlative, and subgroup analyses Daniel J. DeAngelo,
More informationOncology Highlights: Leukemia & Myelodysplastic Syndromes
Oncology Highlights: Leukemia & Myelodysplastic Syndromes Jorge Cortes, MD Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Highlights of the Day Leukemia & MDS AML: The field
More informationCautionary Note Regarding Forward-Looking Statements
lndoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1
More informationSUPPLEMENTARY FIG. S3. Kaplan Meier survival analysis followed with log-rank test of de novo acute myeloid leukemia patients selected by age <60, IA
Supplementary Data Supplementary Appendix A: Treatment Protocols Treatment protocols of 123 cases patients were treated with the protocols as follows: 110 patients received standard DA (daunorubicin 45
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More informationClinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel
Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly
More informationAcute Leukemia From Precision Medicine to ImmunoRx
Acute Leukemia From Precision Medicine to ImmunoRx Hagop M. Kantarjian, MD Professor and Chair, Department of Leukemia Samsung Distinguished Leukemia Chair in Cancer Medicine The University of Texas MD
More informationUnderstanding AML Casey O Connell, MD Associate Professor, Jane Anne Nohl Division of Hematology Keck School of Medicine, USC
First Let s Look at Our Blood Understanding AML Casey O Connell, MD Associate Professor, Jane Anne Nohl Division of Hematology Keck School of Medicine, USC Bone Marrow: The Blood Cell Factory 10,000,000,000
More informationInotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More informationFLT-3 inhibitors in AML
FLT-3 inhibitors in AML Jorge Sierra Hospital de la Santa Creu i Sant Pau Autonomous University of Barcelona Rome, September 24, 2017 Disclosures Advisory board: Pfizer, NovarHs, Jazz, Celgene, SeaIle
More informationDisclosure Slide. Research Support: Onconova Therapeutics, Celgene
Oral Rigosertib Combined with Azacitidine in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): Effects in Treatment Naïve and Relapsed- Refractory Patients Shyamala C. Navada,
More informationAML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered
AML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered Charles A. Schiffer, M.D. Karmanos Cancer Institute Wayne State University School of Medicine Detroit, MI WHY ARE
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research
More informationMolecular Genetic Testing to Predict Response to Therapy in MDS
Molecular Genetic Testing to Predict Response to Therapy in MDS Rafael Bejar MD, PhD Bone Marrow Failure Disease Scientific Symposium Rockville, MD March 18 th, 2016 Overview Response Criteria Lenalidomide
More informationScottish Medicines Consortium
Scottish Medicines Consortium azacitidine 100mg powder for suspension for injection (Vidaza ) No. (589/09) Celgene Ltd 05 March 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationMinimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital
Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital 1. The logistics of MRD assessment in AML 2. The clinical
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationSupplemental Material. The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia
Supplemental Material The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia Torsten Haferlach, 1 Anna Stengel, 1 Sandra Eckstein, 1 Karolína
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationAcute Myeloid Leukemia with RUNX1 and Several Co-mutations
Case SH2017-0281 Acute Myeloid Leukemia with RUNX1 and Several Co-mutations James Bauer, MD, PhD David Yang, MD Erik Ranheim, MD, PhD Catherine Leith, MB, Bchir Clinical History Chief Complaint: 72 year
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationWelcome and Introductions
Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality
More informationDisclosures. Acute Myeloid Leukemia: The Past, the Present, the Future 9/17/18
Acute Myeloid Leukemia: The Past, the Present, the Future Disclosures Research Support: ASH, A.P. Giannini Foundation, Stanford Cancer Institute Other Disclosures: None 1 Learning Objectives AML: the pre-216
More informationCARE at ASH 2014 Leukemia. Julie Bergeron, MD Maisonneuve-Rosemont Hospital
CARE at ASH 2014 Leukemia Julie Bergeron, MD Maisonneuve-Rosemont Hospital Acute Leukemias Dr. Julie Bergeron Hôpital Maisonneuve-Rosemont, Montréal Disclosures Advisory boards in 2014: AMGEN EUSA pharma
More informationDISCLOSURE Luca Malcovati, MD. No financial relationships to disclose
ICUS, CCUS and CHIP Luca Malcovati, MD Department of Molecular Medicine, University of Pavia Medical School, & Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy DISCLOSURE
More informationBlast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome
RESEARCH ARTICLE Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome AJH Mrinal M. Patnaik, 1 Emnet A. Wassie, 1 Terra L. Lasho, 2 Curtis
More informationVYXEOS : CHEMOTHERAPY LIPOSOME INJECTION FOR ACUTE MYELOID LEUKEMIA
VYXEOS : CHEMOTHERAPY LIPOSOME INJECTION FOR ACUTE MYELOID LEUKEMIA Sarah Mae Rogado PharmD Candidate 2017 Preceptors: Rozena Varghese, PharmD, CMPP; Rachel Brown, PharmD MedVal Scientific Information
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationHighlights in acute myeloid leukemia (AML): what is going to change?
29 Highlights in acute myeloid leukemia (AML): what is going to change? C. Graux, MD, PhD SUMMARY The decision making process in AML integrates clinical features, an increasing amount of genetic information
More informationIllumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
More informationHighlights in acute leukemia
CONGRESS HIGHLIGHTS 28 Highlights in acute leukemia T. Feys, MSc, MBA SPECIAL EDITION There has been a long period of time without any new acute myeloid leukemia (AML) treatments. However, the tide has
More informationBlastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
More information